Ensysce Biosciences, Inc.
ENSC
$0.47
$0.000.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 21.16% | -48.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.16% | -48.95% | |||
| Cost of Revenue | -26.15% | -7.37% | |||
| Gross Profit | 45.20% | -37.86% | |||
| SG&A Expenses | 7.88% | 11.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.30% | -3.02% | |||
| Operating Income | 27.67% | -28.05% | |||
| Income Before Tax | 27.71% | -28.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.71% | -28.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.72% | -28.50% | |||
| EBIT | 27.67% | -28.05% | |||
| EBITDA | 27.72% | -27.89% | |||
| EPS Basic | 62.08% | 30.67% | |||
| Normalized Basic EPS | 62.09% | 30.66% | |||
| EPS Diluted | 62.08% | 30.67% | |||
| Normalized Diluted EPS | 62.09% | 30.66% | |||
| Average Basic Shares Outstanding | 90.60% | 85.34% | |||
| Average Diluted Shares Outstanding | 90.60% | 85.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||